Source:http://linkedlifedata.com/resource/pubmed/id/10686191
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2000-4-25
|
| pubmed:abstractText |
In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. Ultimately, 181 patients (96.3%) in the cetrorelix group, and 77 (90.6%) in the buserelin group, reached the day of the human chorionic gonadotrophin (HCG) injection. The mean number of human menopausal gonadotrophin (HMG) ampoules administered and the mean number of stimulation days with HMG were significantly less in the cetrorelix group than in the buserelin group (P < 0.01). A rise in LH and progesterone concentrations was observed in three of the 188 patients (1.6%) who received cetrorelix. On the day of the HCG administration, more follicles of a small diameter (11-14 mm) were observed in the buserelin group than in the cetrorelix group (P = 0. 02) and the mean serum oestradiol concentration was significantly higher in patients who received buserelin than in those who received cetrorelix (P < 0.01). Similar results were observed in fertilization, cleavage and pregnancy rates in the two groups. In conclusion, the use of the LHRH antagonists might be considered more advantageous because of the short-term application needed to inhibit gonadotrophin secretion, so allowing a reduction in the treatment time in a clinically significant manner.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Buserelin,
http://linkedlifedata.com/resource/pubmed/chemical/Chorionic Gonadotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Fertility Agents, Female,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Hormone Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Luteinizing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/cetrorelix
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0268-1161
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
526-31
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10686191-Adult,
pubmed-meshheading:10686191-Buserelin,
pubmed-meshheading:10686191-Chorionic Gonadotropin,
pubmed-meshheading:10686191-Embryo Transfer,
pubmed-meshheading:10686191-Female,
pubmed-meshheading:10686191-Fertility Agents, Female,
pubmed-meshheading:10686191-Gonadotropin-Releasing Hormone,
pubmed-meshheading:10686191-Hormone Antagonists,
pubmed-meshheading:10686191-Humans,
pubmed-meshheading:10686191-Luteinizing Hormone,
pubmed-meshheading:10686191-Oocytes,
pubmed-meshheading:10686191-Ovarian Hyperstimulation Syndrome,
pubmed-meshheading:10686191-Ovulation Induction,
pubmed-meshheading:10686191-Pregnancy,
pubmed-meshheading:10686191-Pregnancy Rate,
pubmed-meshheading:10686191-Progesterone,
pubmed-meshheading:10686191-Prospective Studies,
pubmed-meshheading:10686191-Treatment Outcome
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
|
| pubmed:affiliation |
Centre for Reproductive Medicine, Dutch-speaking Brussels Free University, Belgium.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|